Qure Ventures

Qure Ventures, headquartered in Tel Aviv, was the first venture fund in Israel built exclusively around digital health, and that founding orientation continues to shape its identity. The fund concentrates on companies bringing AI precision to predictive diagnostics, clinical decision support, and care delivery, with a thesis that distinct data assets and credible clinical evidence are the durable sources of advantage in healthcare software.

For AI healthcare founders, the relevant thesis covers digital health platforms, AI-enabled clinical decision support, predictive diagnostics, remote care, and software whose value depends on integrating with real clinical workflows and demonstrating outcomes. Companies whose AI is substantive and whose data strategy is credible fit the fund’s orientation. Pure consumer wellness without a clinical angle, devices, and biotech are outside the mandate. Lightweight enterprise SaaS labeled as healthtech because of customer industry will find limited traction.

Check sizes range from $1M to $5M at entry, deployed at seed and Series A. Qure participates as a lead or co-lead in priced rounds and reserves capital for follow-on. Geography is principally Israel, with portfolio companies typically operating globally and pursuing the US and Europe as primary commercial markets. Syndicate partners include other Israeli digital health specialists, US digital health funds, and selected strategic investors. Reserve strategy is consistent with the long timelines characteristic of regulated healthcare software.

The team carries backgrounds in healthcare investing, clinical operations, and the Israeli digital health ecosystem. Board engagement at seed and Series A tends to be active, with help focused on regulatory pathway, clinical evidence generation, payer and provider commercial strategy, and downstream financing. The fund’s long history in digital health gives it a network of clinical advisors and operators that portfolio companies can draw on substantively.

Founders should approach Qure with a clear articulation of the clinical problem being solved, the data strategy underlying the AI, and the regulatory and evidence path that will make the product credible to providers and payers. Introductions through Israeli and US digital health VCs, clinical operators, or portfolio CEOs are the highest-signal path in. The right time to engage is when the team is assembled, an early product is in motion, and the next round is being structured. Founders pitching consumer wellness, devices, or biotech will not find fit. Companies whose evidence and data strategy is hand-waved rather than serious will struggle to clear diligence. For founders building genuinely thoughtful AI-driven digital health products who want a partner with a long-running thesis specifically in the space, Qure offers capital and operational depth that few Israeli funds can match.